SecBot SecBot
Biotech Drug Report Generated Nov 6, 2026

PIPE-791

CTNM·Contineum Therapeutics, Inc.
NEUTRAL
Drug Impact Rating4/10
Trial phase
Phase 2
Time to market
At least 4-5 years away, if successful. The Phase 2 PROPEL-IPF trial is estimated to complete in June 2028, and a Phase 3 program and regulatory filing would follow, meaning potential approval is likely in the 2030-2032 timeframe at the earliest.
Why 4/10
No hard, dated binary catalyst is scheduled within the next ~12 months. The next major catalyst is the Phase 2 PROPEL-IPF topline readout, estimated to complete in June 2028, which is more than 18 months away. The Phase 1b readouts (chronic pain and PET) are already past. PIPE-791 is the company's lead wholly-owned asset, but with no near-term binary event, the impact score is capped at 4 per the rubric.
Actionable Insight NEUTRAL

PIPE-791 is a mid-stage asset with no near-term binary catalyst; the next major event is the Phase 2 PROPEL-IPF readout estimated for mid-2028. The competitive landscape shifted significantly on October 12, 2026, when BMS's admilparant succeeded in Phase 3 for IPF, potentially becoming the first approved LPAR1 antagonist. Investors should watch for enrollment completion updates and whether Contineum can differentiate PIPE-791 on safety, dosing convenience, or CNS indications (chronic pain, MS) where BMS's compound may not compete.

Price Chart

Loading chart...

Executive Summary

PIPE-791 is Contineum Therapeutics' lead wholly-owned drug candidate, an oral LPAR1 antagonist in Phase 2 development for idiopathic pulmonary fibrosis (IPF), with additional potential in chronic pain. The drug has generated positive Phase 1b data in both a PET receptor-occupancy trial and a chronic pain study. However, the competitive landscape shifted dramatically on October 12, 2026, when Bristol Myers Squibb reported that its rival LPAR1 antagonist admilparant succeeded in a Phase 3 IPF trial and plans regulatory filings. With the Phase 2 PROPEL-IPF readout not expected until mid-2028, CTNM stock faces a long wait with no near-term catalyst and significant competitive overhang. The company has $244.5 million in cash (runway through mid-2029) and a consensus analyst price target of $22.14, but the stock has fallen from its 52-week high of $17.79 to $8.81.

How It Works

PIPE-791 is an oral small-molecule drug that blocks the lysophosphatidic acid receptor 1 (LPAR1), a protein involved in scarring (fibrosis) of the lungs, neuroinflammation, and chronic pain signaling. By blocking this receptor, the drug aims to slow or prevent tissue scarring and reduce pain without opioids.

Trial Status

PIPE-791 is being studied in PROPEL-IPF, a global Phase 2 randomized, double-blind, placebo-controlled trial in approximately 324 patients with idiopathic pulmonary fibrosis (IPF). Dosing began in Q1 2026, with over 100 sites active across 25 countries as of October 2026. The 26-week primary endpoint is change in forced vital capacity (FVC). Estimated completion is June 2028. Two Phase 1b trials have already reported positive topline data: a PET trial (September 2025) showing high brain receptor occupancy, and a chronic pain trial (April 2026) showing consistent improvement across exploratory pain measures. A planned Phase 2 trial in progressive multiple sclerosis was postponed to focus resources on the IPF program.

The Two-Sided Case

▲ Bull Case4
PIPE-791 targets a clinically validated mechanism (LPAR1 antagonism) in IPF, a disease with high unmet need affecting approximately 130,000 people in the US. The Phase 1b PET trial confirmed high brain receptor occupancy, and the Phase 1b chronic pain trial showed positive exploratory efficacy signals, supporting the drug's potential as a differentiated, once-daily oral therapy.
The company has a strong cash position of $244.5 million as of September 30, 2026, providing runway through mid-2029, which funds the Phase 2 program and potential expansion without near-term dilution risk.
Analyst consensus is Buy (6 buy, 3 hold) with a mean price target of $22.14, representing approximately 147% upside from the current $8.81 price. Multiple large institutional holders including BlackRock, Franklin Resources, and Balyasny have accumulated positions.
PIPE-791 may have a safety advantage over competing LPAR1 antagonists: preclinical data suggest it avoids the hepatobiliary toxicity and hypotension issues seen with BMS's earlier-generation compounds, and its once-daily dosing could be more convenient than BMS's admilparant (twice daily).
▼ Bear Case4
Bristol Myers Squibb's admilparant (BMS-986278), a competing LPAR1 antagonist, succeeded in its Phase 3 ALOFT-IPF trial on October 12, 2026, meeting the primary endpoint at the 60 mg dose. BMS plans to file for regulatory approval, which could make admilparant the first approved LPAR1 antagonist for IPF and potentially limit PIPE-791's market opportunity.
The Phase 2 PROPEL-IPF trial is not expected to read out until approximately June 2028, meaning there is no near-term binary catalyst for the stock. The stock has already fallen from its 52-week high of $17.79 to $8.81, reflecting the lack of near-term events and competitive pressure.
Baird downgraded CTNM from Outperform to Neutral on October 14, 2026, and the stock dropped approximately 10% on November 5, 2026. The bull/bear evidence checklist shows a bearish net signal driven by elevated short-sale volume (z-score 2.06), analyst downgrade, insider sales via 10b5-1 plans, and several institutional exits including Baker Bros. and RA Capital.
The company's partnered program with Johnson & Johnson (PIPE-307 for major depressive disorder) missed its Phase 2 primary endpoint, and the company has implemented a workforce reduction and delayed other pipeline programs, signaling pipeline concentration risk on PIPE-791 alone.

Upcoming Catalysts

  • Enrollment updates for the Phase 2 PROPEL-IPF trial (ongoing, no specific date announced)
  • Potential partnership or licensing interest for PIPE-791 in chronic pain or other indications
  • Johnson & Johnson's decision on next steps for PIPE-307 after the Phase 2 MDD miss (could affect sentiment on the broader pipeline)

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Contineum Therapeutics, Inc. 8-K CTNM ·Originating report

Sources · 13

Hover a chip for the title
1 contineum-tx.com2 ir.contineum-tx.com3 ir.contineum-tx.com4 ir.contineum-tx.com5 nasdaq.com6 news.bms.com7 clinicaltrials.gov8 fiercebiotech.com9 biospace.com10 ir.contineum-tx.com11 businesswire.com12 stocktitan.net13 kalkine.ca